together with the panfungal reverse primer in the reamplifi cation step of the snPCR specifi cally amplifi ed rDNA from reference and clinical C. dubliniensis isolates and not from C. albicans or other Candida species. The identity of two representative isolates was confi rmed by DNA sequencing of the ITS2 region. Conclusions: The identity of 12 C. dubliniensis isolates was fi rst established by phenotypic characteristics and then by snPCR using species-specifi c primers derived from ITS2 sequences. The recovery of C. dubliniensis from HIV-negative patients from Kuwait reinforces the existing view that this novel yeast species has a worldwide distribution and its occurrence is not restricted to any particular immunocompromised population.
Introduction
Candida dubliniensis is a newly recognized species that is genotypically distinct from C. albicans but shares several phenotypic characteristics with the latter species [1] . It occurs as a minor constituent of the human oral microfl ora [2] . In the past, C. dubliniensis isolates have been misidentifi ed as C. albicans , since both species are germ tube positive and produce chlamydospores on cornmeal Tween 80 agar [1] [2] [3] . Although initially C. dubliniensis was believed to be associated with oropharyngeal candidiasis in human immunodefi ciency virus (HIV)-infected patients [4, 5] , recent reports suggest that this species has a much wider epidemiologic signifi cance [2] . The species has been isolated from a variety of clinical specimens and anatomic sites of HIV-negative as well as HIV-positive individuals with and without symptoms of oral candidiasis [4] [5] [6] [7] [8] .
Given the growing importance of C. dubliniensis as an opportunistic pathogen [7] [8] [9] , development of rapid methods to discriminate C. dubliniensis from C. albicans is highly desirable. Recently, several seed-based and nonseed-based media have been described to discriminate C. dubliniensis from C. albicans on the basis of colony characteristics and chlamydospores production [10] [11] [12] [13] [14] [15] . Rapid identifi cation of clinical C. dubliniensis isolates has also been described by the use of specifi c primers in PCR [16, 17] .
In this study, we report isolation and identifi cation of 12 isolates of C. dubliniensis from non-HIV-infected patients from Kuwait during a 1-year period. The identification of the C. dubliniensis isolates was performed by phenotypic characteristics and by a semi-nested PCR (sn-PCR) using panfungal and C. dubliniensis -specifi c primers as described in the previous studies [18] [19] [20] .
Materials and Methods

Isolation and Phenotypic Characterization
A total of 880 clinical specimens (vaginal swab: 410; urine: 123; bronchoalveolar lavage: 85; sputum: 81; cerebrospinal fl uid: 46; blood culture: 40; tracheal secretion: 36; peritoneal and gastric fl uid: 21; throat swab: 14; wound swab: 7; catheter tip: 7; tissue biopsies: 6, and bile fl uid: 4) for the isolation of fungi received at the Mycology Laboratory during January to December 2003 were processed according to standard procedures as previously described [21] . All the yeast isolates (n = 452) were streaked on Sabouraud glucose agar (glucose 15 g, peptone 10 g and agar 15 g in 1 liter distilled water, pH 6.8) supplemented with chloramphenicol (50 mg/l) and checked for purity. The inoculum from the isolated yeast colonies was tested for germ tube formation in serum at 37 ° C. The germ tube-positive isolates (390) were examined for colonial and microscopic characteristics on simplifi ed sunfl ower seed agar as previously described [10] . Isolates producing rough colonies with hyphal fringes and chlamydospores were provisionally identifi ed as C. dubliniensis. They were further identifi ed by their inability to assimilate trehalose and ␣ -methyl-D -glucoside in the Vitek 2 yeast identifi cation system (BioMerieux, Marey l'Etoile, France). Isolates were also tested for tolerance to 6.5% sodium chloride to distinguish C. dubliniensis from C. albicans [22] . 
Molecular
snPCR Amplifi cation Method
The genomic DNA was extracted from the grown cultures of the isolates as previously described [18, 19] . The sequences of the universal forward and reverse fungal primers, capable of amplifying the 3 end of 5.8S and 5 end of 28S rDNA including the internally transcribed spacer 2 (ITS2) region and the species-specifi c oligonucleotide primer, derived from the ITS2 region of C. dubliniensis, have already been described [18] [19] [20] . Amplifi cation with universal fungal primers and species-specifi c primer together with universal fungal reverse primer in the fi rst round and snPCR from C. dubliniensis CD 36 should yield DNA fragments of 350 bp and 105 bp, respectively [20] . Amplifi cation of target DNA was carried out in thin-walled 0.2-ml PCR tubes in a total volume of 50 l containing 1 ! AmpliTaq PCR buffer I, 1 U AmpliTaq DNA polymerase, 10 pmol each of CTSF and CTSR primers, 1 l of DNA and 0.1 m M of each dNTP. After amplifi cation in the fi rst step, 1 l of the product was further amplifi ed using the initial reverse primer (CTSR) and C. dubliniensis -specifi c forward primer. For snPCR, the reaction mixture consisted of 1 ! AmpliTaq PCR buffer I, 1 U AmpliTaq DNA polymerase, 5 pmol of CTSR together with 5 pmol of CDDET; 1 l of the fi rst PCR product and 0.1 m M of each dNTP. PCR cycling (total 30 cycles) was carried out in a PerkinElmer cycler (GeneAmp PCR system 2400) under the following conditions: denaturation at 94 ° C for 1 min, annealing at 60 ° C for 30 s and extension at 72 ° C for 1 min. An initial denaturation step at 95 ° C for 3 min and a fi nal extension step at 72 ° C for 10 min were also included. To detect amplifi ed DNA fragments, agarose gel electrophoresis was performed as previously described [18] . The gels were exposed to UV light and photographed. Appropriate negative controls were included in each test run, including controls omitting the DNA template during PCR assays.
The DNA sequence of the ITS2 region of two representative clinical C. dubliniensis isolates from Kuwait (MF 1042 and MF 122) was determined by amplifi cation of the ITS2 region with universal fungal primers. The sequencing reactions with amplifi ed DNA as template and forward or reverse panfungal primer were performed as described elsewhere [23] . Briefl y, the column-purifi ed PCR-amplifi ed fragment obtained with the panfungal primer pair was used as template in sequencing reactions using the cycle DNA sequencing kit (DTCS CEQ2000, Beckman Coulter). The reaction mixtures in a fi nal volume of 20 l contained eluted DNA, 5 pmol of CTSF or CTSR primer and 8.0 l of the premix reaction components supplied in the kit. The cycling parameters for the sequencing reactions included an initial denaturation at 95 ° C for 5 min followed by 30 cycles of 1 min at 94 ° C, 30 s at 55 ° C and 2 min at 60 ° C. The reaction products were precipitated and loaded on the sequencer as directed by the manufacturer of the automated DNA sequencer (Beckman Coulter Model CEQ8000).
Antifungal Susceptibility Testing
Antifungal susceptibility of the 12 C. dubliniensis isolates was determined against amphotericin B, fl uconazole and voriconazole by E-test (AB BIODISK, Solna, Sweden). Each C. dubliniensis isolate was freshly subcultured and checked for purity. Five isolated colonies were uniformly suspended in sterile saline solution and turbidity was adjusted to 0.5 on the McFarland standard scale. This inoculum was then streaked onto the Sabouraud dextrose agar Petri plates (150 mm diameter) and allowed to dry at room temperature for 10-15 min before the application of the E-test strips. The RPMI-1640 agar supplemented with 2% glucose and buffered with MOPS, 0.165 M , pH 7.0, was used for antifungal susceptibility testing (National Committee for Clinical Laboratory Standards, NC-CLS, M-27A) [24] . The plates were incubated in an incubator at 35 ° C for 1-2 days and minimal inhibitory concentrations (MICs) were read after 24-48 h of incubation. The point where inhibition ellipses intercepted the scale on the antifungal strip was taken as MIC for each test isolate. Complete inhibition (100%) of growth for amphotericin B and marked decrease in growth intensity for fl uconazole and voriconazole were observed [25, 26] .
Results
Of the 390 germ tube-positive isolates of Candida species, 12 were identifi ed as C. dubliniensis based on colonial and microscopic characteristics on simplifi ed sunfl ower seed agar medium. All the 12 C. dubliniensis isolates formed rough colonies with hyphal fringes and abundant chlamydospores on this medium after 48 h of incubation at 30 ° C ( fi g. 1 a, b), while none of the remaining 378 isolates exhibited these characteristics. The results of phenotypic and genotypic characterization and the antifungal susceptibility profi le are presented in tables 1, 2 and fi gures 1-3 . Among the 12 isolates of C. dubliniensis , 9 were recovered from the respiratory tract and 1 each from urine, vaginal swab and catheter tip. All the 12 C. dubliniensis isolates originated from HIV-negative patients and none of these patients had systemic Candida infection. None of the 12 C. dubliniensis isolates assimilated ␣ -methyl-D -glucoside, lactate and trehalose after 24 h of incubation in the Vitek 2 yeast identifi cation system. Four C. dubliniensis isolates assimilated D -xylose. The growth of C. dubliniensis isolates was inhibited in the presence of 6.5% sodium chloride ( table 1 ) .
The results of the E-test performed on the 12 C. dubliniensis isolates are presented in table 2 . The E-test MIC ranges for the three antifungal agents were as follows: amphotericin B 0.002-0.038 g/ml, fl uconazole 0.094-0.75 g/ml, and voriconazole 0.003-0.012 g/ml. None of C. dubliniensis isolate was resistant to any of the three antifungal agents tested.
The PCR amplifi cation of rDNA from the 7 Candida species, i.e., C. albicans, C. dubliniensis, C. parapsilosis, C. tropicalis , C. glabrata, C. krusei and C. lusitaniae, using universal fungal primers (CTSF and CTSR) resulted in amplifi cation of DNA fragments of expected sizes ( fi g. 2 a). Similar results were obtained when the genomic DNA prepared from A. fumigatus, F. solani, T. asahii and C. neoformans was used as template (data not shown). Reamplifi cation of the product of the fi rst PCR with CTSR and CDDET resulted in specifi c amplifi cation of a single DNA fragment of the expected size from the reference strain of C. dubliniensis only and not from the 6 The PCR amplifi cation of rDNA from all the 12 clinical isolates of C. dubliniensis recovered from Kuwait, using CTSF and CTSR primers, resulted in specifi c amplifi cation of a single DNA fragment of the expected size (the data from four isolates are shown in fi gure 2 a, lanes 1-4) from each isolate. Further, reamplifi cation of the products of the fi rst PCR with CTSR and CDDET resulted again in specifi c amplifi cation of a single DNA 
Discussion
This study reports recovery of 12 isolates of C. dubliniensis from a range of clinical samples and originating from patients with different underlying conditions within a span of 1 year. The identity of the isolates has been unequivocally established as C. dubliniensis by known phenotypic and molecular characteristics. In most of the published studies, differences in the assimilation of xylose, trehalose, and ␣ -methyl-D -glucoside have been used to separate C. dubliniensis from C. albicans [1, 27, 28] . However, some recent reports suggest that assimilation characteristics of carbohydrates between the 2 species are not as discriminatory as initially reported and may vary depending upon the assimilation method employed [29, 30] . The ability of 4 of our C. dubliniensis isolates to assimilate D -xylose within 24 h with the Vitek 2 yeast identifi cation system also suggests the inconsistency of the assimilation profi les in distinguishing these two closely related Candida species. Using a novel automated assimilation system, Kurzai et al. [30] reported that C. dubliniensis isolates were able to utilize D -xylose and trehalose. In another study [29] , while the 24-hour profi les obtained with the Vitek 2 yeast identifi cation system showed that ␣ -methyl-D -glucoside, D -xylose and glycerol could be used to separate C. dubliniensis from C. albicans, at 48 h only D -xylose (6 vs. 95%) was useful for separating the two species. Following comparative evaluation of different commercial systems, these investigators [29] concluded that the assimilation of ␣ -methyl-D -glucoside, D -xylose and trehalose was most useful for the differentiation of the two species by the majority of commercial systems. Moreover, it was the rapidity of the assimilation achieved with the commercial systems that allowed the differentiation of C. dubliniensis from C. albicans. [29] [30] [31] [32] . As our understanding on the occurrence and pathogenesis of this novel species is increasing, it is becoming apparent that this pathogen has the potential to cause a wide spectrum of clinical conditions both in HIV-infected and non-HIV-infected patients such as those receiving chemotherapy for cancer, organ transplant recipients or patients with other underlying conditions [2, 4, 6, 8, 33, 34] . A review of published reports suggests that C. dubliniensis is widely distributed in the population but forms only a minor constituent of the microbial fl ora in HIV-negative individuals [1, 2, 32] . Although the species may be found at any anatomic site, it probably exhibits greater propensity to colonize oral mucosa particularly of HIVinfected patients [2, 4, 5, 34, 35] . In our study, none of the C. dubliniensis isolates came from HIV-infected patients, but as many as 9 of the 12 (75%) were isolated from respiratory tract specimens ( table 1 ) . The other three isolates were recovered from catheter tip, urine and vaginal specimens. Other studies have also reported the isolation of C. dubliniensis from a wide range of clinical specimens including bronchoalveolar lavage, urine and catheter tip [37, 38] . In a study of the Irish population of normal healthy individuals, only 3.5% were found to carry C. dubliniensis in the oral cavity, while the prevalence of this species in the vagina was found to be even lower (2.7%) [34] . In contrast, 26% of HIV-infected and 32% of AIDS patients with symptoms of oropharyngeal candidiasis yielded C. dubliniensis, whereas in patients without symptoms of oropharyngeal candidiasis the colonization levels were 18 and 25%, respectively [35] . Like in other regions of the world [2, 32] , occurrence of C. dubliniensis has also been recognized in the Middle East [20, 33, 34, [36] [37] [38] .
Fotedar and Al-Hedaithy [38] studied 823 germ tubepositive and chlamydospore-positive C. albicans isolates at the University Hospital in Riyadh, Saudi Arabia. On reexamination, 27 (3.3%) of them were identifi ed as C. dubliniensis. The prevalence of C. dubliniensis amongst germ tube-positive isolates was almost similar (3%) in the present study.
It has been suggested that the recent emergence of C. dubliniensis as a human pathogen may have resulted due to the widespread use of azole antifungal therapy in HIV-infected patients, in a manner similar to that suggested for C. glabrata [1, 2] . However, this assumption may not be correct since it has been found that the great majority of C. dubliniensis isolates are inherently susceptible to commonly used antifungal agents [5, 39] . Similarly, all the 12 C. dubliniensis isolates of this study were susceptible to fl uconazole and voriconazole and also to amphotericin B.
Conclusions
We have described the isolation and identifi cation of 12 isolates of C. dubliniensis recovered mostly from the respiratory tract of HIV-negative patients in Kuwait during a 1-year period. As our understanding of the epidemiology of C. dubliniensis is increasing, it is becoming apparent that this pathogen can colonize different anatomic sites with a potential to cause superfi cial or invasive disease.
